oa Journal of Endocrinology, Metabolism and Diabetes in South Africa - Product news



Extracted from text ... 35 May 2006, Vol. 11, No. 1 JEMDSA Protos: The first dual-action bone agent for osteoporosis Servier Laboratories recently announced the launch of its new osteoporosis drug Protos (strontium ranelate) in South Africa. Indicated for the treatment of postmenopausal osteoporosis to reduce the risk of both vertebral and non-vertebral fractures, including the hip, 1 Protos is a new first-line option in the treatment of postmenopausal osteoporosis. The first in a new therapeutic class, Protos is categorised as a 'dual action bone agent'. Whereas other therapies either prevent bone loss (the antiresorptive agents) or promote bone formation only (the anabolic agents), ..


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error